CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting treatment effectiveness.

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...